Factors associated with the emergence of ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
Auteur(s) :
Marcelin, Anne-Genevieve [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Charpentier, Charlotte [Auteur]
Infection, Anti-microbiens, Modélisation, Evolution [IAME (UMR_S_1137 / U1137)]
Bellecave, Pantxika [Auteur]
Microbiologie Fondamentale et Pathogénicité [MFP]
Abdi, Basma [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Chaix, Marie-Laure [Auteur]
Evolution et pathogenèses virales
Ferre, Virginie [Auteur]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Raymond, Stephanie [Auteur]
Institut Toulousain des Maladies Infectieuses et Inflammatoires [Infinity]
Fofana, Djeneba [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Bocket, Laurence [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Mirand, Audrey [Auteur]
CHU Clermont-Ferrand
Le Guillou-Guillemette, Helene [Auteur]
Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques [HIFIH]
Montes, Brigitte [Auteur]
Laboratoire de Virologie [CHRU Montpellier]
Amiel, Corinne [Auteur]
CHU Tenon [AP-HP]
Pallier, Coralie [Auteur]
Hôpital Paul Brousse
Fafi-Kremer, Samira [Auteur]
Université de Strasbourg [UNISTRA]
De Monte, Anne [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Alessandri-Gradt, Elodie [Auteur]
CHU Rouen
Scholtes, Caroline [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Maillard, Anne [Auteur]
Laboratoire de Virologie [Rennes] = Virology [Rennes]
Jeulin, Helene [Auteur]
Service de Virologie [CHRU Nancy]
Bouvier-Alias, Magali [Auteur]
Service de bactériologie, virologie, hygiène [Mondor]
Roussel, Catherine [Auteur]
Laboratoire de Virologie [CHU Amiens]
Dos Santos, Georges [Auteur]
Laboratoire de Virologie-Immunologie [Fort de France, Martinique] [EA 4537]
Signori-Schmuck, Anne [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Dina, Julia [Auteur]
Université de Caen Normandie [UNICAEN]
Vallet, Sophie [Auteur]
Université de Brest [UBO]
Stefic, Karl [Auteur]
Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents [MAVIVHe]
Soulié, Cathia [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Calvez, Vincent [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Descamps, Diane [Auteur]
Microbiologie Fondamentale et Pathogénicité [MFP]
Flandre, Philippe [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Charpentier, Charlotte [Auteur]
Infection, Anti-microbiens, Modélisation, Evolution [IAME (UMR_S_1137 / U1137)]
Bellecave, Pantxika [Auteur]
Microbiologie Fondamentale et Pathogénicité [MFP]
Abdi, Basma [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Chaix, Marie-Laure [Auteur]
Evolution et pathogenèses virales
Ferre, Virginie [Auteur]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Raymond, Stephanie [Auteur]
Institut Toulousain des Maladies Infectieuses et Inflammatoires [Infinity]
Fofana, Djeneba [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Bocket, Laurence [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Mirand, Audrey [Auteur]
CHU Clermont-Ferrand
Le Guillou-Guillemette, Helene [Auteur]
Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques [HIFIH]
Montes, Brigitte [Auteur]
Laboratoire de Virologie [CHRU Montpellier]
Amiel, Corinne [Auteur]
CHU Tenon [AP-HP]
Pallier, Coralie [Auteur]
Hôpital Paul Brousse
Fafi-Kremer, Samira [Auteur]
Université de Strasbourg [UNISTRA]
De Monte, Anne [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Alessandri-Gradt, Elodie [Auteur]
CHU Rouen
Scholtes, Caroline [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Maillard, Anne [Auteur]
Laboratoire de Virologie [Rennes] = Virology [Rennes]
Jeulin, Helene [Auteur]
Service de Virologie [CHRU Nancy]
Bouvier-Alias, Magali [Auteur]
Service de bactériologie, virologie, hygiène [Mondor]
Roussel, Catherine [Auteur]
Laboratoire de Virologie [CHU Amiens]
Dos Santos, Georges [Auteur]
Laboratoire de Virologie-Immunologie [Fort de France, Martinique] [EA 4537]
Signori-Schmuck, Anne [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Dina, Julia [Auteur]
Université de Caen Normandie [UNICAEN]
Vallet, Sophie [Auteur]
Université de Brest [UBO]
Stefic, Karl [Auteur]
Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents [MAVIVHe]
Soulié, Cathia [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Calvez, Vincent [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Descamps, Diane [Auteur]
Microbiologie Fondamentale et Pathogénicité [MFP]
Flandre, Philippe [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Titre de la revue :
Journal of Antimicrobial Chemotherapy
Nom court de la revue :
J Antimicrob Chemother
Numéro :
76
Pagination :
2400–2406
Date de publication :
2021-06-10
ISSN :
1460-2091
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
Résumé en anglais : [en]
Background
Successful 2-drug regimens (2DRs) for HIV were made possible by the availability of drugs combining potency and tolerability with a high genetic barrier to resistance. How these deal with resistance ...
Lire la suite >Background Successful 2-drug regimens (2DRs) for HIV were made possible by the availability of drugs combining potency and tolerability with a high genetic barrier to resistance. How these deal with resistance development/re-emergence, compared with 3DRs, is thus of paramount importance. Materials and methods A national survey including patients who were either naive or experienced with any 2DR or 3DR but failing integrase strand transfer inhibitor (INSTI)-containing regimens [two consecutive plasma viral load (VL) values >50 copies/mL] was conducted between 2014 and 2019. Genotypic resistance tests were interpreted with the v28 ANRS algorithm. Results Overall, 1104 patients failing any INSTI-containing regimen (2DRs, n = 207; 3DRs, n = 897) were analysed. Five hundred and seventy-seven (52.3%) patients were infected with a B subtype and 527 (47.3%) with non-B subtypes. Overall, 644 (58%) patients showed no known integrase resistance mutations at failure. In multivariate analysis, factors associated with the emergence of at least one integrase mutation were: high VL at failure (OR = 1.24 per 1 log10 copies/mL increase); non-B versus B subtype (OR = 1.75); low genotypic sensitivity score (GSS) (OR = 0.10 for GSS = 2 versus GSS = 0–0.5); and dolutegravir versus raltegravir (OR = 0.46). Although 3DRs versus 2DRs reached statistical significance in univariate analysis (OR = 0.59, P = 0.007), the variable is not retained in the final model. Conclusions This study is one of the largest studies characterizing integrase resistance in patients failing any INSTI-containing 2DR or 3DR in routine clinical care and reveals factors associated with emergence of integrase resistance that should be taken into consideration in clinical management. No difference was evidenced between patients receiving a 2DR or a 3DR.Lire moins >
Lire la suite >Background Successful 2-drug regimens (2DRs) for HIV were made possible by the availability of drugs combining potency and tolerability with a high genetic barrier to resistance. How these deal with resistance development/re-emergence, compared with 3DRs, is thus of paramount importance. Materials and methods A national survey including patients who were either naive or experienced with any 2DR or 3DR but failing integrase strand transfer inhibitor (INSTI)-containing regimens [two consecutive plasma viral load (VL) values >50 copies/mL] was conducted between 2014 and 2019. Genotypic resistance tests were interpreted with the v28 ANRS algorithm. Results Overall, 1104 patients failing any INSTI-containing regimen (2DRs, n = 207; 3DRs, n = 897) were analysed. Five hundred and seventy-seven (52.3%) patients were infected with a B subtype and 527 (47.3%) with non-B subtypes. Overall, 644 (58%) patients showed no known integrase resistance mutations at failure. In multivariate analysis, factors associated with the emergence of at least one integrase mutation were: high VL at failure (OR = 1.24 per 1 log10 copies/mL increase); non-B versus B subtype (OR = 1.75); low genotypic sensitivity score (GSS) (OR = 0.10 for GSS = 2 versus GSS = 0–0.5); and dolutegravir versus raltegravir (OR = 0.46). Although 3DRs versus 2DRs reached statistical significance in univariate analysis (OR = 0.59, P = 0.007), the variable is not retained in the final model. Conclusions This study is one of the largest studies characterizing integrase resistance in patients failing any INSTI-containing 2DR or 3DR in routine clinical care and reveals factors associated with emergence of integrase resistance that should be taken into consideration in clinical management. No difference was evidenced between patients receiving a 2DR or a 3DR.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2024-01-17T22:13:41Z
2024-02-13T12:47:46Z
2024-02-13T12:47:46Z
Fichiers
- document
- Accès libre
- Accéder au document